Current and former members of the FDA told CNN about issues with the Elsa generative AI tool unveiled by the federal agency last month. Three employees said that in practice, Elsa has hallucinated ...

The FDA is still on track to meet its user fee targets despite a higher-than-normal vacancy rate among scientific reviewers.

A recipient of the 2025 Elite Trial Lawyers Lifetime Achievement Award, Morgan & Morgan's John Yanchunis spoke with the National Law Journal about his storied career, from bringing one of the nation’s ...

Dr. George Tidmarsh, a Stanford pediatrics adjunct professor and former pharmaceutical executive, is FDA Commissioner Marty ...

Two months after laying off 20% of its staff, Korro Bio says it has not retreated from its “3-2-1” corporate strategy as it prepares to release interim clinical data on its lead candidate KRRO-110 in ...

Martin Muoto’s real estate funds at Sola Impact were examined by the regulator over intercompany deals and allegations of ...

Dr. Peter Marks, the former director of the FDA’s Center for Biologics Evaluation and Research, urged public health leaders ...

Sarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the FDA.

Decriminalization was a three-year pilot project introduced by the BC NDP to help people access harm reduction services and ...

MTX-001 recognized for its clinical and commercial potential for treating chronic non-healing venous leg ulcers (VLUs)RESEARCH TRIANGLE PARK, N.C., July 24, 2025 (GLOBE NEWSWIRE) -- Merakris ...

Sarepta Therapeutics’ stock has dropped precipitously as questions swirl around the safety of its gene therapies. Meanwhile, the Duchenne patient community fears losing access to Elevidys while the ...

The American Benefits Council is urging Congress to consider the cost to employers, workers and their families as it proposes ...